Zhailaubay Kydyrbayev, N. N. Asanjanova, S. Ryskeldinova, E. M. Kozhamkulov, E. K. Kulbekov, E. T. Myrzakhmetov, Zh. A. Tursynova, N. Z. Akmyrzaev
{"title":"APPROBATION TRIALS OF A VACCINE AGAINST NEWCASTLE DISEASE FROM THE LA SOTA STRAIN","authors":"Zhailaubay Kydyrbayev, N. N. Asanjanova, S. Ryskeldinova, E. M. Kozhamkulov, E. K. Kulbekov, E. T. Myrzakhmetov, Zh. A. Tursynova, N. Z. Akmyrzaev","doi":"10.58318/2957-5702-2022-9-34-43","DOIUrl":null,"url":null,"abstract":"the paper presents the results of an approbation test of the physical and biological properties of an experimental series of a vaccine against Newcastle disease from the La-Sota strain in the conditions of the National Reference Center for Veterinary Medicine of the Committee for Veterinary Control and Supervision of the Ministry of Agriculture of the Republic of Kazakhstan (CVC and SMA RK) and the Research Institute of Biological Problems security (RIBSP). The aim of the study was to test a vaccine against Newcastle disease from the La-Sota strain. When performing the work, general virological and immunological research methods were used. The results of approbation studies showed that the vaccine was free of contaminants and its biological activity was 9,03 ± 0,14 lg EID50/cm3. The vaccine is harmless to chickens of 40 days of age. The vaccine is immunogenic for chickens. The average titers of antibodies to the Newcastle disease virus on the 16th day after vaccination is 1:127,2 in the hemagglutination inhibition test (HITA). The vaccine meets all the required requirements in terms of its physico-biological properties and is suitable for specific prophylaxis of Newcastle disease. Approbation tests of the physical, biological properties of the vaccine were completed with positive results and protocols, research acts were signed by members of the Commission of the CVC and SMA RK. It is recommended to use the vaccine on a large scale in the conditions of poultry farms, private farmsteads for the specific prevention of Newcastle disease.","PeriodicalId":307725,"journal":{"name":"Biosafety and Biotechnology","volume":"82 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biosafety and Biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.58318/2957-5702-2022-9-34-43","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
the paper presents the results of an approbation test of the physical and biological properties of an experimental series of a vaccine against Newcastle disease from the La-Sota strain in the conditions of the National Reference Center for Veterinary Medicine of the Committee for Veterinary Control and Supervision of the Ministry of Agriculture of the Republic of Kazakhstan (CVC and SMA RK) and the Research Institute of Biological Problems security (RIBSP). The aim of the study was to test a vaccine against Newcastle disease from the La-Sota strain. When performing the work, general virological and immunological research methods were used. The results of approbation studies showed that the vaccine was free of contaminants and its biological activity was 9,03 ± 0,14 lg EID50/cm3. The vaccine is harmless to chickens of 40 days of age. The vaccine is immunogenic for chickens. The average titers of antibodies to the Newcastle disease virus on the 16th day after vaccination is 1:127,2 in the hemagglutination inhibition test (HITA). The vaccine meets all the required requirements in terms of its physico-biological properties and is suitable for specific prophylaxis of Newcastle disease. Approbation tests of the physical, biological properties of the vaccine were completed with positive results and protocols, research acts were signed by members of the Commission of the CVC and SMA RK. It is recommended to use the vaccine on a large scale in the conditions of poultry farms, private farmsteads for the specific prevention of Newcastle disease.
本文介绍了在哈萨克斯坦共和国农业部兽医控制和监督委员会国家兽医参考中心(CVC和SMA RK)和生物问题安全研究所(RIBSP)的条件下,对La-Sota菌株抗新城疫的实验系列疫苗的物理和生物学特性进行批准测试的结果。这项研究的目的是测试一种针对La-Sota菌株的新城疫疫苗。在开展工作时,采用了一般病毒学和免疫学研究方法。审定结果表明,该疫苗无污染,生物活性为9.03±0.14 lg EID50/cm3。这种疫苗对40日龄的鸡无害。这种疫苗对鸡具有免疫原性。接种后第16天的新城疫病毒血凝抑制试验(HITA)抗体平均滴度为1:27 7,2。该疫苗在物理生物学特性方面满足所有要求,适用于新城疫的特异性预防。疫苗的物理和生物特性的批准试验已完成,取得了积极的结果,并签署了协议,研究行为由疫苗安全委员会和疫苗安全协会RK委员会成员签署。建议在有条件的家禽养殖场、私人养殖场大规模使用疫苗,以专门预防新城疫。